Skip to main content

Citi Reaffirms Their Buy Rating on Regeneron (REGN)

Tipranks - Tipranks - Fri Feb 20, 1:56AM CST

Citi analyst Geoff Meacham maintained a Buy rating on Regeneron yesterday. The company’s shares closed yesterday at $792.16.

President's Day Sale - 70% Off

According to TipRanks, Meacham is a 5-star analyst with an average return of 8.6% and a 58.28% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Eli Lilly & Co, and Gilead Sciences.

Currently, the analyst consensus on Regeneron is a Strong Buy with an average price target of $870.90, representing a 9.94% upside. In a report released on February 17, Canaccord Genuity also maintained a Buy rating on the stock with a $1,057.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Regeneron’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.88 billion and a net profit of $844.6 million. In comparison, last year the company earned a revenue of $3.79 billion and had a net profit of $917.7 million

Read More on REGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).